Zydus Lifesciences Ltd on Monday said the US health regulator USFDA has concluded an inspection at its manufacturing facility at SEZ II in Ahmedabad with one observation.
The US Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practice inspection at the plant from September 21-28, 2026, the company said in a regulatory filing.
The inspection closed with one observation, and there were no data integrity-related observations, it added.
Zydus Lifesciences said it will work closely with the USFDA to address the observation expeditiously.
Published on September 29, 2026
